We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Analysis of Volatile Substances in Breath of Pneumonia Patients Confirms Fungal Infection Diagnosis

By LabMedica International staff writers
Posted on 03 Nov 2014
Analysis of volatile substances in the breath of patients with respiratory infections has been proposed as a novel, noninvasive, pathogen-specific approach to identifying the precise microbial cause of pneumonia.

Investigators at Brigham and Women's Hospital (Boston, MA, USA) were particularly interested in the fungus Aspergillus fumigatus, which causes an often fatal type of pneumonia in patients with compromised immune systems.

The investigators first identified unique volatile substances produce by A. More...
fumigatus growing in Petri dishes and then used thermal desorption-gas chromatography/mass spectrometry to attempt to detect these substances in the breath of pneumonia patients.

Among the distinctive substances produced by cultures of A. fumigatus that could be used to distinguish it from other pathogenic aspergilli were the monoterpenes camphene, alpha- and beta-pinene, and limonene and the sesquiterpene compounds alpha- and beta-trans-bergamotene.

The investigators analyzed breath samples that had been collected from 2011 to 2013 from 64 patients with suspected invasive fungal pneumonia. Results revealed that of the 64 patients who had been diagnosed with suspected invasive fungal pneumonia based on host risk factors, clinical symptoms, and radiological findings, 34 were diagnosed with invasive aspergillosis, whereas 30 were ultimately diagnosed with other causes of pneumonia, including other invasive fungal infection. Detection of alpha-trans-bergamotene, beta-trans-bergamotene, a beta-vatirenene-like sesquiterpene, or trans-geranylacetone identified invasive aspergillosis patients with 94% sensitivity and 93% specificity.

"Identification of the underlying microbial etiology remains elusive in most patients with pneumonia, even with invasive diagnostic measures," said first author Dr. Sophia Koo, assistant professor of medicine at Brigham and Women's Hospital. "Our findings provide proof-of-concept that we can harness detection of species-specific metabolites to identify the precise microbial cause of pneumonia, which may guide appropriate treatment of these infections. We can likely also use this volatile metabolite profiling approach to identify other, more common causes of pneumonia."

The proof-of-concept study was published in the October 22, 2014, online edition of the journal Clinical Infectious Diseases.

Related Links:

Brigham and Women's Hospital





Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.